In this study, we have designed a cost effective targeted gene panel to investigate the mutational landscape of 4 high impact breast cancer genes (BRCA1, BRCA2, ERBB2 and TP53) in breast tumor and in blood. The gene discussed is TP53; the disease is breast neoplasm.